Affiliation:
1. 1st Department of Urology, Medical University of Lodz, 93-513 Lodz, Poland
Abstract
Bladder cancer is the 10th most popular cancer in the world, and non-muscle-invasive bladder cancer (NMIBC) is diagnosed in ~80% of all cases. Treatments for NMIBC include transurethral resection of the bladder tumor (TURBT) and intravesical instillations of Bacillus Calmette-Guérin (BCG). Treatment of BCG-unresponsive tumors is scarce and usually leads to Radical Cystectomy. In this paper, we review recent advancements in conservative treatment of BCG-unresponsive tumors. The main focus of the paper is FDA-approved medications: Pembrolizumab and Nadofaragene Firadenovec (Adstiladrin). Other, less researched therapeutic possibilities are also included, namely: N-803 immunotherapy, TAR-200 and TAR-210 intravesical delivery systems and combined Cabazitaxel, Gemcitabine and Cisplatin chemotherapy. Conservative treatment and delaying radical cystectomy would greatly benefit patients’ quality of life; it is undoubtedly the future of BCG-unresponsive NMIBC.
Reference71 articles.
1. Centers for Disease Control and Prevention (2020). Male Urologic Cancers, Centers for Disease Control and Prevention, US Department of Health and Human Services. USCS Data Brief, no 21.
2. Sex disparities in cancer incidence by period and age;Cook;Cancer Epidemiol. Biomark. Prev.,2009
3. Kaseb, H., and Aeddula, N.R. (2024, February 02). Bladder Cancer. [Updated 2022 October 24], StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK536923/.
4. The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients;Bruins;World J. Urol.,2023
5. Prediction of non-muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features;Tokuyama;Mod. Pathol.,2022
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献